Company intelligence / Profile preview

Epigenomics

Berlin, Berlin, Germanyepigenomics.com ↗

Ownership: Private
Employees: ~6
Development stage: Commercial

Overview

Epigenomics AG develops molecular diagnostics based on DNA methylation biomarkers for early detection of cancers such as colorectal, lung, and prostate. Its lead product is Epi proColon®, a blood-based liquid biopsy test for colorectal cancer. The company has published over 60 peer-reviewed scientific articles in the last decade. It operates globally with headquarters in Berlin and Seattle.

Therapeutic areas: Oncology
Modalities: Liquid biopsyDNA methylation-based diagnostics
Industry: Molecular Diagnostics

Partnerships

BioChainVSA ALTA COMPLEJIDAD S.A.

Beyond the preview

Go deeper on Epigenomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epigenomics.

Explore the full profile